# Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass

> **NCT02025621** · PHASE3 · COMPLETED · sponsor: **Tenax Therapeutics, Inc.** · enrollment: 882 (actual)

## Conditions studied

- Coronary Artery Bypass Grafting
- Mitral Valve Surgery
- Low Cardiac Output Syndrome

## Interventions

- **DRUG:** Levosimendan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02025621
- **Lead sponsor:** Tenax Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 882 (ACTUAL)
- **Last updated:** 2018-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02025621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02025621, "Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02025621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*